-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cerebral malaria (CM) is still responsible for unacceptable death rate, while new antimalarial drugs were recently developed. CM pathophysiology shares essential biological features with cerebral ischemia. Because erythropoietin (Epo) was demonstratedto reduce mortality rate during experimental cerebral ischemia (1), in the early 2000, we wondered whether Epo could helpto reduce the burden of CM. There is now evidence that Epo high doses could prevent early mortality during cerebral malaria. This evidence was obtained first using mice model of cerebral malaria, and later confirmed by prospective clinical trial inendemic area. High doses of Epo are needed to cross the blood–brain barrier (
seeNote 1
) and to favor the cytoprotective versus hematopoietic effect of this pleiotropic cytokine (
seeNote 2
).